Uptal Patel is Chief Medical Officer at HI-Bio. Prior to HI-Bio, he was the Head of Clinical Renal and Executive Group Director in Early CVRM at AstraZeneca where he led early clinical strategy and development for a wide range of therapies that address several kidney diseases. Dr. Patel attended medical school at UCSF and completed residency and fellowship training at the University of Michigan. He also received advanced training in health services research and epidemiology, and has been board certified in internal medicine, pediatrics, adult nephrology, and pediatric nephrology. He was faculty in the adult and pediatric nephrology divisions at Duke University and a member of the Duke Clinical Research Institute where he was interested in developing and applying strategies to reduce the burden of kidney disease in populations. There, he directed several multidisciplinary translational research efforts, and led a broad-based research program focused on improving the detection and management of kidney disease, as well as understanding the inter-relationships between kidney disease and cardiovascular disease. He also served on a number of national committees related to clinical research, health policy, and public health issues related to kidney diseases, as well as a several editorial boards, grant review panels, and national committees.

Despite the promise of scalable interventions to improve population health for patients with kidney diseases, these experiences also highlighted the need for more effective & personalized therapies. As a result, he transitioned to industry in 2016 to lead clinical development programs for kidney diseases initially at Gilead Sciences and more recently at AstraZeneca. He remains active in efforts to improve population health for patients with kidney diseases as an Adjunct Professor at Duke.